Americas · Regional markets · Financial Post

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma

Published by Financial Post · Canada 2 h ago

SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical…

Read the full article on Financial Post Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (financialpost.com)

Also worth reading

BNN Bloomberg

Alberta’s oil advantage comes with a costly catch as Bank of Canada raises interest rates

Gestión

Noveno retiro de AFP podría enfrentar un obstáculo: ¿qué rol tiene el TC?

Portafolio

Reforma pensional: Cámara de Representantes subsanó los artículos que la Corte Constitucional pidió revisar

Diario Financiero

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma

Share

Also worth reading

Alberta’s oil advantage comes with a costly catch as Bank of Canada raises interest rates

Noveno retiro de AFP podría enfrentar un obstáculo: ¿qué rol tiene el TC?

Reforma pensional: Cámara de Representantes subsanó los artículos que la Corte Constitucional pidió revisar

Decenas mueren en choque de trenes en España